Quantum BioPharma Ltd.

CNSX:QNTM Stock Report

Market Cap: CA$13.5m

Quantum BioPharma Management

Management criteria checks 3/4

Quantum BioPharma's CEO is Zeeshan Saeed, appointed in Jul 2021, has a tenure of 3.33 years. total yearly compensation is $599.87K, comprised of 37.1% salary and 62.9% bonuses, including company stock and options. directly owns 6.11% of the company’s shares, worth CA$826.31K. The average tenure of the management team and the board of directors is 3.2 years and 3.2 years respectively.

Key information

Zeeshan Saeed

Chief executive officer

US$599.9k

Total compensation

CEO salary percentage37.1%
CEO tenure3.3yrs
CEO ownership6.1%
Management average tenure3.2yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Apr 13
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Dec 17
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

Aug 25
Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

How Many FSD Pharma Inc. (CSE:HUGE) Shares Did Insiders Buy, In The Last Year?

Feb 13
How Many FSD Pharma Inc. (CSE:HUGE) Shares Did Insiders Buy, In The Last Year?

CEO Compensation Analysis

How has Zeeshan Saeed's remuneration changed compared to Quantum BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$600kUS$223k

-US$18m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$774kUS$239k

-US$27m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$30m

Dec 31 2021US$1mUS$225k

-US$34m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$30m

Dec 31 2020US$899kUS$212k

-US$28m

Sep 30 2020n/an/a

-US$36m

Jun 30 2020n/an/a

-US$35m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$2mUS$249k

-US$34m

Sep 30 2019n/an/a

-US$38m

Jun 30 2019n/an/a

-US$25m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018US$503kUS$183k

-US$17m

Compensation vs Market: Zeeshan's total compensation ($USD599.87K) is above average for companies of similar size in the Canadian market ($USD169.37K).

Compensation vs Earnings: Zeeshan's compensation has been consistent with company performance over the past year.

CEO

Zeeshan Saeed (54 yo)

3.3yrs

Tenure

US$599,873

Compensation

Mr. Zeeshan Saeed serves as Executive Co-Chairman at FSD Pharma Inc. since May 24, 2018 and serves as its President since July 27, 2021 and Chief Executive Officer since June 29, 2023. He serves as Co-Chai...

Leadership Team

NamePositionTenureCompensationOwnership
Zeeshan Saeed
Founder3.3yrsUS$599.87k6.11%
CA$ 826.3k
Anthony Durkacz
Founder & Executive Co-Chairman6.4yrsUS$599.87k5.21%
CA$ 705.0k
Donal Carroll
CFO & COO3.3yrsUS$602.87k4.31%
CA$ 583.2k
Nathan Coyle
Controllerless than a yearUS$178.21k0.13%
CA$ 17.6k
Lakshmi Kotra
CEO of Lucid & Director3.2yrsUS$521.97k1.14%
CA$ 154.3k
Jason Sawyer
Head of Finance & Mergers and Acquisitionsless than a yearno datano data
Maryann Adesso
Corporate Secretaryno datano datano data
Randell Mack
President of FSD BioSciences3.7yrsno datano data
Andrzej Chruscinski
Vice President of Clinical & Scientific Affairs of Lucidno dataUS$110.30k0%
CA$ 0
Kevin Cassidy
Vice President of Quality-Lucidno dataUS$144.82kno data

3.2yrs

Average Tenure

48yo

Average Age

Experienced Management: QNTM's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zeeshan Saeed
Founder3.5yrsUS$599.87k6.11%
CA$ 826.3k
Anthony Durkacz
Founder & Executive Co-Chairman6.4yrsUS$599.87k5.21%
CA$ 705.0k
Lakshmi Kotra
CEO of Lucid & Director2yrsUS$521.97k1.14%
CA$ 154.3k
Daniele Piomelli
Member of Research & Clinical Advisory Board2.8yrsno datano data
Eleanor Fish
Member of Research & Clinical Advisory Board3yrsno datano data
Hance Clarke
Member of Research & Clinical Advisory Board3.2yrsno datano data
Eric Hoskins
Independent Director1.5yrsno datano data
Adnan Bashir
Independent Director3.4yrsUS$139.37k0.0075%
CA$ 1.0k
Peter Stys
Member of Research & Clinical Advisory Board3.2yrsno datano data
Shannon Dunn
Member of Research & Clinical Advisory Board3.2yrsno datano data
Albert Wong
Member of Research & Clinical Advisory Board3.2yrsno datano data
Joga Gobburu
Member of Regulatory Advisory Board3yrsno datano data

3.2yrs

Average Tenure

54yo

Average Age

Experienced Board: QNTM's board of directors are considered experienced (3.2 years average tenure).